Delving into the Latest Updates on Glycine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target-

Action

modulators

Mechanism

Amino acid modulators

Therapeutic Areas

Other DiseasesEndocrinology and Metabolic DiseaseHemic and Lymphatic Diseases+ [1]

Active Indication

Dietary SupplementDiabetic NephropathiesAnemia, Sideroblastic

Inactive Indication

NeuralgiaSchizophrenia

Originator Organization

Hospira, Inc.

Active Organization

Peking University

B. Braun Medical, Inc.Baxter Healthcare Corp.

+ [3]

Inactive Organization

Hospira, Inc.

AstraZeneca Pharmaceuticals Co. Ltd.

Yale University

+ [1]

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (25 May 1976),

Dietary Supplement

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC2H5NO2

InChIKeyDHMQDGOQFOQNFH-UHFFFAOYSA-N

CAS Registry56-40-6

The aim of this clinical trial is to evaluate and compare the effect of a newly designed air-polishing device (APD) using Erythritol, Glycine, and Trehalose air-polishing powders in nonsurgical periodontal therapy with control (conventional scaling and root planning) following the concept of guided biofilm therapy (GBT) as an adjunctive to subgingival instrumentation (SI) in nonsurgical periodontal therapy for Stage II and III periodontitis patients both clinically and microbiologically.

Start Date03 Mar 2024

Sponsor / Collaborator

Alexandria University

100 Clinical Results associated with Glycine

Login to view more data

100 Translational Medicine associated with Glycine

Login to view more data

100 Patents (Medical) associated with Glycine

Login to view more data

130,308

Literatures (Medical) associated with Glycine

31 Dec 2025·International Journal of Food Properties

FTIR characteristics of sweet flour as affected by particle size distribution and in vitro digestibility of gluten-free sweet potato noodles

Author: Mohamed Ahmed, Isam A. ; Qureshi, Tahir Mahmood ; Wadood, Syed Abdul ; Ali, Asmahan A. ; Azeem, Muhammad ; Anees Ur Rehman, Muhammad ; Aljobair, Moneera O.

There is a need to explore the influence of particle size of sweet potato flour on physicochem. properties and in vitro starch digestibility of gluten free sweet potato noodles.The aim of this work was to examine the influence of purple-fleshed sweet potato flour (PFSPF) having different particle size distribution (355 μm to 75μ m) on physicochem. properties and in vitro starch digestibility of gluten-free purple sweet potato noodles.Pasting properties and sugar contents were pos. correlated toward the finest particle fraction.The hardness of noodles was pos. and significantly correlated to the finest particle size fraction.Sweet potato flour (SPF) noodles prepared with particle size of 75 μm retained lower hardness 5.74 N.An abrupt increase in yellowness was observed with decreasing particle size that might be attributed to the reduction of protein.The results of FTIR suggested that with the reduction of particle size, protein and carbohydrates decreased that much associated with crystallization and retrogradation of starch.Among all the amino acids, aspartic acid and glutamic acid were observed to be more abundant, i.e. approx. 13.33 and 29.05‰, resp.In this way, PFSPF with particle size 75 μm exhibited significant application potential for producing gluten free noodles due to high resistant starch and lower hardness.It may be concluded that particle sizes of sweet potato flour influenced pasting properties, textural characteristics, sugar contents, protein contents, amino acid contents, carbohydrate contents of prepared noodles.

31 Dec 2025·mAbs

Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing

Article

Author: Pantazes, Robert J. ; Islam, Sumaiya ; Chauhan, Varun M.

Antibody repurposing is the process of changing a known antibody so that it binds to a mutated antigen. One of the findings to emerge from the Coronavirus Disease 2019 (COVID-19) pandemic was that it was possible to repurpose neutralizing antibodies for Severe Acute Respiratory Syndrome, a related disease, to work for COVID-19. Thus, antibody repurposing is a possible pathway to prepare for and respond to future pandemics, as well as personalizing cancer therapies. For antibodies to be successfully repurposed, it is necessary to know both how antigen mutations disrupt their binding and how they should be mutated to recover binding, with this work describing an analysis to address the first of these topics. Every possible antigen point mutation in the interface of 246 antibody-protein complexes were analyzed using the Rosetta molecular mechanics force field. The results highlight a number of features of how antigen mutations affect antibody binding, including the effects of mutating critical hotspot residues versus other positions, how many mutations are necessary to be likely to disrupt binding, the prevalence of indirect effects of mutations on binding, and the relative importance of changing attractive versus repulsive energies. These data are expected to be useful in guiding future antibody repurposing experiments.

31 Dec 2025·Virulence

Staphylococcus aureus nt5 gene mutation through CRISPR RNA-guided base editing weakens bacterial virulence and immune evasion

Article

Author: Wang, Haiyi ; Zhang, Peng ; Dai, Ruiwu ; Liu, Xinpeng ; Huang, Lan ; He, Fuqiang ; Ye, Yang ; Xia, Zijing ; Deng, Shi ; Tang, Min ; Liang, Shufang

The resistance of commonly used clinical antibiotics, such as daptomycin (DAP), has become increasingly serious in the fight against Staphylococcus aureus (S. aureus) infection. It is essential to explore key pathogenicity-driven genes/proteins in bacterial infection and antibiotics resistance, which contributes to develop novel therapeutic strategies against S. aureus infections. The nt5 gene of S. aureus, encoding 5'-nucleotidase (NT5), is nearly unknown for its function in drug resistance and bacterial infection. Herein, to reveal nt5 gene role in drug resistance and infection ability of S. aureus, we performed nt5^C166T gene mutation using a clustered regulatory interspaced short palindromic repeat ribonucleic acid (RNA)-guided base editing system to investigate the lose-of-function of NT5 protein. Subsequent transcriptome sequencing of the mutant strain revealed that nt5 inactivation caused changes in cell membrane integrity and inhibited nucleotide metabolism, suggesting the nt5 gene may be involved in bacterial drug resistance and virulence. The mutant strain exhibited enhanced tolerance to DAP treatment by attenuating cell membrane potential dissipation and slowing deoxyribonucleic acid release. Moreover, the nt5 mutation alleviated abscess degree of mouse kidneys caused by S. aureus infection byreducing the expression of IL-1β, IL-6, and IL-18. The nt5 mutant strain was easily swallowed by host immune cells, resulting in weak bacterial toxicity of the S. aureus mutant in the bacterial infection process. In summary, nt5 gene mutation confers tolerance to DAP and a lower bacterial capacity to form kidney abscesses through phagocytosis of host immune cells, which indicates the targeted inhibition of NT5 protein would offer a potential new therapeutic strategy against S. aureus infection.

100 Deals associated with Glycine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00011	Glycine	B05CX03	DB00145

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dietary Supplement	United States	B. Braun Medical, Inc.	06 Feb 1978

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neuralgia	Phase 3	Europe	AstraZeneca PLC	-
Neuralgia	Phase 3	-	AstraZeneca Pharmaceuticals Co. Ltd.	-
Diabetic Nephropathies	Preclinical	China	Peking University	15 Sep 2016
Anemia, Sideroblastic	Preclinical	Canada	IWK Health Centre	18 Nov 2012
Anemia, Sideroblastic	Preclinical	Canada	Dalhousie University	18 Nov 2012
Schizophrenia	Preclinical	United States	Yale University	01 Mar 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04443673 (Pubmed)	Not Applicable	COVID-19	-	Glycine by enteral route	bzpawfrbko(ztypibwdde) = omjuhybhfl zgobjtvfhe (yjgbppxjqo, 17.7) View more	Negative	21 May 2024
				Glycine (Usual care)	bzpawfrbko(ztypibwdde) = bqjpsxnxcx zgobjtvfhe (yjgbppxjqo, 25.0) View more
EADV2023	Not Applicable	-	-	Herbal extract combination (Dihydroquercetin glucoside, Epigallocatechin gallate glucoside, zinc and glycine)	twbcunxdsr(fzroncfucf) = No local adverse effects were observed in both groups joffuhwhys (fzpbjxlbxr )	Positive	11 Oct 2023
				3% minoxidil solution
FRN 143219 (CIHR) \| 82100702 (NSFC) (EASD2023)	Not Applicable	Nesidioblastosis	-	Glycine	zryyqmifkn(ywqkmdzlir) = jwvhqjqhdx hexaktbndl (nawildxnjx ) View more	Positive	05 Oct 2023
				β-alanine	zryyqmifkn(ywqkmdzlir) = feukmpbjju hexaktbndl (nawildxnjx ) View more
EASD2019	Not Applicable	Diabetes Mellitus	-	Diabetic rats receiving glycine treatment	oumgoyhtbh(upcughlunj) = opkxlzkguv cwmavyoohz (hinbseuukx )	-	19 Sep 2019
NCT00338598 (CTgov)	Phase 2	Schizophrenia	20	Glycine (Glycine)	xlsmmmoncs(ahpxkyyaac) = tekhuxmgax knyqbfhawh (xnlfnaozmg, gcqjgzilot - vcjhkkoxne) View more	-	12 Apr 2017
				placebo (Placebo)	xlsmmmoncs(ahpxkyyaac) = zztwcmrxjr knyqbfhawh (xnlfnaozmg, lbkhlysslp - sdrtueksqx) View more
NCT00291226 (CTgov)	Phase 2/3	Schizophrenia	8	Glycine (Glycine)	vusgvypnml(qhdvndgist) = odukdazwcr twhxdfygvl (evtudkeffd, nqfkmkenca - mvwciqkawt) View more	-	29 Dec 2016
				Placebo (Placebo Group)	vusgvypnml(qhdvndgist) = izkimzhemn twhxdfygvl (evtudkeffd, secgsqavir - dafopmeygz) View more
OP 24 (EASD2016)	Not Applicable	Insulinoma plasma glycine concentrations \| insulin sensitivity \| obesity	-	Glycine (Healthy donors)	texpzyghlt(oipbjfurow) = qurzqvmdzj gezgtutxpd (kupwuigzpf ) View more	Positive	14 Sep 2016
				Glycine (Donors with T2D)	myqzvubvcs(mcujscrlxk) = mgothidsow ytfshziqxu (pyxoakpuve ) View more
ECCO2013	Not Applicable	-	-	Glycine	qeyjneqitc(gywcoymgkc) = qvuxksqnxc owuifglyzn (qpowhzessu )	-	01 Feb 2013
				Glycine (Glutamine)	qeyjneqitc(gywcoymgkc) = babedqaeqm owuifglyzn (qpowhzessu )
SFN2009	Not Applicable	-	-	Glycine	vtaqwfmzac(xnuatgnimt) = mmvtjxiyah cgtnkcmspr (mjukccesaq )	-	18 Oct 2009
Pubmed \| J Nutr	Not Applicable	-	-	[1,2-13C2]Glycine	iwdapwxuxs(ehdyobkxtj) = wzueqcrvcm suhpsdcyja (xdtlqegdfs ) View more	-	01 Dec 2007